At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 45 target
Drug / intervention
Candesartan +1 moredrug
Likely dose
Candesartan 8 mgfrom record
Key inclusion· 1
- ✓Chronic hepatitis C
Key exclusion· 2
- ✕Acute hepatitis
- ✕Thalassemia
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C
In Brief
A Phase 3 clinical trial evaluating Candesartan and Ramipril for Liver Fibroses. Currently recruiting, targeting 45 participants across 1 site.
Detailed Summary
Effect of Some Drugs on Liver Fibrosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Fibroses
CountriesEgypt
Collaborators--
Timeline
Phase 3Recruiting
2019202020212022202320242025202620272028
Enrollment StartOct 2018
First PostedDec 2018
TodayJul 2026
Primary CompletionOct 2026
Study CompletionNov 2027
First PostedDec 10, 2018
Enrollment StartOct 1, 2018
Primary CompletionOct 1, 2026
Study CompletionNov 1, 2027
TodayJul 2, 2026
Enrollment to primary: 8 yearsPosted 7.6 years agoPrimary completion in 3 months
Interventions
Candesartandrug
Candesartan 8 mg/day
Ramiprildrug
ramipril 1.25 mg/day